5 years of historical data (2020–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Centessa Pharmaceuticals plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $3.6B | $1.9B | $766M | $290M | $1.0B | — |
| Enterprise Value | $3.3B | $1.7B | $722M | $-34302410 | $494M | — |
| P/E Ratio → | -13.04 | — | — | — | — | — |
| P/S Ratio | — | — | 111.71 | — | — | — |
| P/B Ratio | 7.66 | 4.78 | 3.24 | 0.86 | 2.06 | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 105.38 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -73.9% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | — | — | — |
| Operating Margin | — | — | -2499.4% | — | — | — |
| Net Profit Margin | — | — | -2204.7% | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -73.9% | -73.9% | -52.8% | -52.2% | -154.4% | -344.2% |
| ROA | -50.3% | -50.3% | -37.6% | -40.3% | -119.1% | -91.0% |
| ROIC | -91.8% | -91.8% | -125.3% | -1291.7% | — | — |
| ROCE | -47.9% | -47.9% | -47.1% | -42.0% | -123.3% | -337.0% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $383M exceeds total debt of $117M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.29 | 0.36 | 0.21 | 0.15 | 1.82 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.66 | -0.18 | -0.96 | -1.06 | -0.52 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -19.93 | -19.93 | -17.29 | -29.17 | -147.08 | -27.62 |
Net cash position: cash ($383M) exceeds total debt ($117M)
Short-term solvency ratios and asset-utilisation metrics
Centessa Pharmaceuticals plc's current ratio of 9.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 11.42x to 9.25x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 9.25 | 9.25 | 8.00 | 11.42 | 25.52 | 1.30 |
| Quick Ratio | 9.25 | 9.25 | 8.00 | 11.42 | 25.52 | 1.30 |
| Cash Ratio | 8.31 | 8.31 | 6.51 | 10.27 | 24.15 | 0.84 |
| Asset Turnover | — | — | 0.02 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 2085.08 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Centessa Pharmaceuticals plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $114M | $96M | $93M | $90M | $71M |
Compare CNTA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CNTAYou | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| TECX | $439M | -6.0 | — | — | — | — | -206.6% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 5 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CNTA stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonCentessa Pharmaceuticals plc's current P/E ratio is -13.0x. This places it at the 50th percentile of its historical range.
Centessa Pharmaceuticals plc's return on equity (ROE) is -73.9%. The historical average is -135.5%.
Based on historical data, Centessa Pharmaceuticals plc is trading at a P/E of -13.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.